I rate iShares US Medical Devices ETF a buy, as its recent selloff offers an attractive entry into industry-leading medical device innovators. IHI's top holdings—Abbott Laboratories, Intuitive Surgical, and Boston Scientific—drive growth through strong fundamentals, product innovation, and exposure to secular healthcare trends. Despite higher fees (0.38%) and volatility, IHI's concentrated exposure to medical devices positions it for long-term capital appreciation over more diversified healthcare ETFs.
IHI Corporation (IHICY) Q3 2026 Earnings Call Prepared Remarks Transcript
iShares U.S. Medical Devices ETF offers targeted exposure to U.S. medical device leaders, benefiting from demographic shifts and innovation, but is highly concentrated in top holdings. Current valuation metrics (P/E 31x, P/B 4.6x) are too high; I recommend holding and waiting for a price drop before buying. Industry growth is fueled by an aging population and technological advances like AI and 3D printing, supporting a strong long-term outlook.
IHI CORP (IHICY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
IHI CORP (IHICY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Here is how IHI CORP (IHICY) and Intellicheck Mobilisa, Inc. (IDN) have performed compared to their sector so far this year.
Here is how IHI CORP (IHICY) and DXP Enterprises (DXPE) have performed compared to their sector so far this year.
If you are looking for stocks that are well positioned to maintain their recent uptrend, IHI CORP (IHICY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
IHI CORP (IHICY) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
IHI's strategy provides exposure to the medical devices industry via a representative index sampling method. Here, I illustrate the fund has added zero risk-adjusted active return above the SPY these past 5 years. For those seeking to deviate from the benchmark and get bang for their buck, my recommendation is to avoid IHI for now.
iShares U.S. Medical Devices ETF has stocks that are still dealing with tough comps from COVID-19, though those pressures are vanishing now. IHI multiples remain really high, which is a bit of a concern given where long-term rates are and the greater effect that rates have on stocks with large horizon values. We'd probably stay away from this pick still.
Here is how IHI CORP (IHICY) and Kadant (KAI) have performed compared to their sector so far this year.